China NMPA Drug Inspection - Guizhou Baili Pharmaceutical Group Co., Ltd. - Golden Capsules

China NMPA drug inspection for Guizhou Baili Pharmaceutical Group Co., Ltd. published August 23, 2020. Drug: Golden Capsules. On August 23, 2020, the Ningxia Hui Autonomous Region Drug Administration released Announcement No. 73, detailing the re

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Guizhou Baili Pharmaceutical Group Co., Ltd.

Inspection Date

Unknown Date

Product Type

ID: 81ace349-bd7b-4855-aba5-e5b0d0c06e3f

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox